Nippon Chemiphar will provide extensive preclinical and clinical data that will enable SOM to
initiate a Phase II Proof of Concept study of 30 patients at 3 centers in Europe beginning in
December 2017. Additionally, Nippon Chemiphar will provide formulated ingredients for
clinical trials.
ttp://sombiotech.com/wp-content/uploads/2017/10/NC-and-SOM-Press-Release-Draft-01-Clean_added_PRrev-enviar-RI.pdf
Nippon Chemiphar will provide extensive preclinical and clinical data that will enable SOM to
initiate a Phase II Proof of Concept study of 30 patients at 3 centers in Europe beginning in
December 2017. Additionally, Nippon Chemiphar will provide formulated ingredients for
clinical trials.
ttp://sombiotech.com/wp-content/uploads/2017/10/NC-and-SOM-Press-Release-Draft-01-Clean_added_PRrev-enviar-RI.pdf
一定の収益と配当があって、新薬開発も進行中。
うまく行けば、12月中に導出先で治験開始、マイル収入あるかもと期待。
1~2ヶ月の遅れはザラにありますし、契約内容は不明ですが、海外展開でP2から開始できるのはプラス材料。